Swiss pharmaceutical company Sandoz is expanding its biosimilar pipeline through a new agreement with Henlius, incorporating up to ten active pharmaceutical ingredients into its development portfolio.
The strategic collaboration involves potential payments of up to $322 million. With this transaction, Sandoz continues to strengthen its commercial and development footprint in the global biosimilar market.
